Newcastle spinout Newcells receives six-figure investment from Northstar Ventures for drug discovery platform.

Newcells Biotech, a spinout of Newcastle University developing drug discovery and development products, has secured a six-figure sum from Northstar Ventures.

The cash will be used to further develop Newcells’ technology, based around pluripotent stem cells, which can be used to reprogram adult cells to reproduce indefinitely and transform into other cell types, reducing the need for embryonic stem cells.

Mike Nicholds, CEO at Newcells, said: “The investment we have received will let us build on our research to bring our products and services to drug discovery and disease modelling teams in the biotechnology industry and academy.”